pruritus – Medxy AI

Pruritus in Primary Sclerosing Cholangitis: Prevalence, Persistence, and Association with Disease Severity

By MedXY 08/17/2026

This multicenter study reveals that pruritus affects one in four patients with primary sclerosing cholangitis (PSC), persists over time, and correlates with disease severity, underscoring its clinical significance and guiding future therapeutic strategies.

Gastroenterology news

Seladelpar Significantly Reduces Itch and Sleep Disturbance in PBC: Pooled Phase 3 Evidence and Clinical Implications

By MedXY 11/06/2025

Pooled analysis of the ENHANCE and RESPONSE phase 3 trials shows seladelpar 10 mg reduces pruritus and sleep disturbance in patients with primary biliary cholangitis (PBC) and moderate-to-severe baseline itch versus placebo over 6 months, with an acceptable safety profile.

Clinical Updates Nephrology news Specialties

Efficacy and Safety of Anrikefon in Haemodialysis Patients with Pruritus: Insights from a Phase 3 Multicentre Randomised Controlled Trial

By MedXY 08/21/2025

This phase 3 trial demonstrates that anrikefon significantly reduces pruritus intensity and improves quality of life in patients undergoing haemodialysis with moderate to severe chronic kidney disease-associated pruritus, with a favorable safety profile.

Clinical Updates Gastroenterology news Specialties

Unraveling the Drivers of Pruritus Severity in Intrahepatic Cholestasis of Pregnancy: Insights from a Longitudinal Cohort Study

By MedXY 07/30/2025

Peak bile acid levels and higher maternal BMI independently predict pruritus worsening in intrahepatic cholestasis of pregnancy, emphasizing the need for tailored monitoring and management as gestation advances.

Clinical Updates Medical News Nephrology Specialties

Managing Chronic Kidney Disease-Associated Pruritus: Advances and Clinical Strategies

By MedXY 07/30/2025

CKD-associated pruritus affects up to 85% of dialysis patients and significantly impairs quality of life. Stepwise management, including novel therapies like nemolizumab, is essential for effective symptom control and improved patient outcomes.